Canaccord Lifts PT on BioMarin Pharmaceutical (BMRN) to $104 From $98 – Here’s Why

Core Viewpoint - BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is considered a promising investment opportunity in the biotech sector, with recent price target adjustments from various analysts indicating mixed but generally positive sentiment towards the stock [1][2][3]. Group 1: Analyst Ratings and Price Targets - Canaccord raised the price target for BioMarin to $104 from $98 while maintaining a Buy rating, noting a slight top-line beat in fiscal Q4 2025 earnings [1] - Guggenheim reduced its price target for BioMarin to $86 from $106 but kept a Buy rating on the shares [2] - Bernstein increased its price target to $94 from $90, maintaining an Outperform rating, highlighting that revenues of $875 million exceeded expectations by 5%, although EPS of 46 cents fell short by 16% due to a write-down not factored into consensus [3] Group 2: Company Overview and Product Pipeline - BioMarin specializes in developing and commercializing therapies for serious and life-threatening medical conditions and rare diseases [4] - The company's product pipeline includes key therapies such as Valoctocogene roxaparvovec, Vosoritide, and BMN 307 [4]